CDK2 Inhibition Restores BRD4 Occupancy and Immune Gene Expression to Overcome Checkpoint Resistance in Preclinical Models

The team used genetic CDK2 knockout and the inhibitor tegtociclib in syngeneic models, measuring tumor regression, survival, and dendritic cell activation alongside chromatin occupancy of BRD4. High cyclin E-CDK2 activity correlated with poor clinical responses in the Cancer Immunology Data Engine database. This mechanism extends beyond proliferation control to direct immune evasion, a link not emphasized in ongoing CDK2 trials limited to cyclin E-amplified ovarian and breast cancers.

Prior work on BRD4 in interferon signaling and cyclin E in cell-cycle progression provides context, yet this study is the first to connect the axis to immunotherapy resistance in solid tumors. Observational database correlations require prospective validation, and the dual tumor-plus-dendritic cell effects raise questions about optimal dosing windows and potential autoimmune toxicities not captured in short-term mouse experiments.

Dana-Farber plans a clinical trial combining CDK2 inhibition with PD-1 blockade. Remaining uncertainties include whether cyclin E amplification will serve as a reliable predictive biomarker and how resistance to the combination might emerge through alternative kinase pathways.